Supersensitivity psychosis and aripiprazole tapering

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 33, Issue 4, 2009, Pages 748-749

  Pae, Chi Un ^a,b  

^a The Catholic University of Korea   (South Korea)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; OLANZAPINE;

CHOLINERGIC REBOUND; CORPUS STRIATUM; DISEASE EXACERBATION; DYSKINESIA; EMERGENT WITHDRAWAL DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LETTER; LIMBIC CORTEX; NEUROTRANSMISSION; POSITIVE SYNDROME; PSYCHOSIS; SCHIZOPHRENIA; SUPERSENSITIVITY PSYCHOSIS; SYNDROME;

ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PIPERAZINES; PSYCHOTIC DISORDERS; QUINOLONES;

EID: 67349270888     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2009.03.028     Document Type: Letter

References (9)

1. Davis J.M., and Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 24 (2004) 192-208
2. Grunder G., Fellows C., Janouschek H., Veselinovic T., Boy C., Brocheler A., et al. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am J Psychiatry 165 (2008) 988-995
3. Kegeles L.S., Slifstein M., Frankle W.G., Xu X., Hackett E., Bae S.A., et al. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology 33 (2008) 3111-3125
4. Lambert T.J. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. J Clin Psychiatry 68 Suppl 6 (2007) 10-13
5. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand 114 (2006) 3-13
6. Tadori Y., Kitagawa H., Forbes R.A., McQuade R.D., Stark A., and Kikuchi T. Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912. Eur J Pharmacol 574 (2007) 103-111
7. Tadori Y., Forbes R.A., McQuade R.D., and Kikuchi T. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 607 (2009) 35-40
8. Urban J.D., Vargas G.A., von Zastrow M., and Mailman R.B. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology 32 (2007) 67-77
9. Yokoi F., Grunder G., Biziere K., Stephane M., Dogan A.S., Dannals R.F., et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 27 (2002) 248-259